Literature DB >> 16620539

A comprehensive study on the variations in urinary concentrations of endogenous gamma-hydroxybutyrate (GHB).

Marc A LeBeau1, Madeline A Montgomery, Cynthia Morris-Kukoski, Jason E Schaff, Anna Deakin, Barry Levine.   

Abstract

This study was designed to supplement previous attempts to establish an accurate range of normal endogenous gamma-hydroxybutyrate (GHB) concentrations in random antemortem urine samples. Furthermore, its purpose was to ascertain the effect of gender, race, age, medications, and select medical conditions on endogenous concentrations of GHB in urine and the proposed endogenous urinary GHB cutoff of 10 microg/mL. Urine samples (n = 207) were provided by subjects who reported that they had never used GHB. As part of the collection process, subjects also completed a short survey to collect information about gender, race, age, orally ingested medications, and select medical conditions. All specimens were analyzed in duplicate for the presence of endogenous GHB using a previously reported headspace gas chromatography-mass spectrometry method. The data were analyzed for tendencies among different population groups. GHB concentrations ranged from 0.00 to 2.70 microg/mL in all specimens, with a median concentration of 0.24 microg/mL. Males (n = 130) had an average endogenous GHB concentration of 0.27 microg/mL (0.00-2.70 microg/mL), whereas females (n = 77) averaged 0.29 microg/mL (0.00-0.98 microg/mL). Select medical conditions and participants' race, age ranges, and medications that were used within 48 h prior to collection were also evaluated. We believe this to be the most comprehensive study on endogenous GHB concentrations in urine to date. The results of this study will aid the interpretation of low GHB concentrations measured in urine samples, particularly in investigations of drug-facilitated crimes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16620539     DOI: 10.1093/jat/30.2.98

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  5 in total

Review 1.  Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse.

Authors:  Lawrence P Carter; Daniel Pardi; Jane Gorsline; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2009-06-02       Impact factor: 4.492

2.  Urinary Profile of Endogenous Gamma-Hydroxybutyric Acid and its Biomarker Metabolites in Healthy Korean Females: Determination of Age-Dependent and Intra-Individual Variability and Identification of Metabolites Correlated With Gamma-Hydroxybutyric Acid.

Authors:  Suji Kim; Suein Choi; Min Seo Lee; Mingyu Kim; Maria Park; Sungpil Han; Seunghoon Han; Hye Suk Lee; Sooyeun Lee
Journal:  Front Pharmacol       Date:  2022-04-13       Impact factor: 5.988

Review 3.  GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome.

Authors:  Francesco P Busardò; Alan W Jones
Journal:  Curr Neuropharmacol       Date:  2015-01       Impact factor: 7.363

Review 4.  Metabolic Alterations Associated with γ-Hydroxybutyric Acid and the Potential of Metabolites as Biomarkers of Its Exposure.

Authors:  Suryun Jung; Suji Kim; Yujin Seo; Sooyeun Lee
Journal:  Metabolites       Date:  2021-02-10

5.  Influence of Sex on Urinary Organic Acids: A Cross-Sectional Study in Children.

Authors:  Marianna Caterino; Margherita Ruoppolo; Guglielmo Rosario Domenico Villani; Emanuela Marchese; Michele Costanzo; Giovanni Sotgiu; Simone Dore; Flavia Franconi; Ilaria Campesi
Journal:  Int J Mol Sci       Date:  2020-01-16       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.